Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary

GBI Research’s new report, “Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.
- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.
- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Arthritis Therapeutics Market to 2018 - Introduction 12
3 Arthritis Therapeutics Market to 2018 - Market Overview 14
3.1 Introduction 14
3.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 15
3.2.1 Revenue 15
3.2.2 Annual Cost of Treatment 16
3.3 Treatment Usage Patterns 17
3.3.1 Diseased Population 18
3.3.2 Treatment Seeking Population 18
3.3.3 Diagnosis Population 18
3.3.4 Prescription Population 19
4 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 20
4.1 Osteoarthritis Therapeutics Market 20
4.1.1 Introduction 20
4.1.2 Epidemiology 21
4.1.3 Symptoms 21
4.1.4 Diagnosis 21
4.1.5 Diagnostic Imaging Techniques 22
4.1.6 Treatment 22
4.1.7 Revenue 25
4.1.8 Annual Cost of Treatment 26
4.1.9 Treatment Usage Patterns 27
4.1.10 Marketed Products 29
4.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 30
4.2.1 Drivers for the Osteoarthritis Therapeutics Market 30
4.2.2 Barriers for the Osteoarthritis Therapeutics Market 30
4.3 Opportunity and Unmet Need 31
4.4 Arthritis Therapeutics Market 32
4.4.1 Introduction 32
4.4.2 Epidemiology 33
4.4.3 Symptoms 33
4.4.4 Diagnosis 34
4.4.5 Diagnostic Techniques 34
4.4.6 Treatment 35
4.4.7 Non-Pharmacological Therapy 36
4.4.8 Surgical Treatment 36
4.4.9 Pharmacological Therapy 36
4.4.10 Revenue 37
4.4.11 Annual Cost of Treatment 38
4.4.12 Treatment Usage Patterns 39
4.4.13 Marketed products 41
4.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 42
4.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 42
4.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 42
4.6 Opportunity and Unmet Needs 43
4.7 Psoriatic Arthritis Therapeutics Market 43
4.7.1 Introduction 43
4.7.2 Epidemiology 44
4.7.3 Symptoms 44
4.7.4 Diagnosis 44
4.7.5 Diagnostic Techniques 44
4.7.6 Treatment 45
4.7.7 Non-Pharmacological Therapy 45
4.7.8 Pharmacological Therapy 45
4.7.9 Surgery 46
4.7.10 Revenue 46
4.7.11 Annual Cost of Treatment 47
4.7.12 Treatment Usage Patterns 48
4.7.13 Marketed Products 50
4.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 51
4.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 51
4.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 51
4.9 Opportunity and Unmet Needs 51
4.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 52
4.10.1 Introduction 52
4.10.2 Epidemiology 52
4.10.3 Symptoms 53
4.10.4 Diagnosis 53
4.10.5 Treatment 54
4.10.6 Non-Pharmacological Therapy 54
4.10.7 Pharmacological Therapy 55
4.10.8 Surgery 56
4.10.9 Revenue 56
4.10.10 Annual Cost of Treatment 57
4.10.11 Treatment Usage Patterns 58
4.10.12 Marketed products 60
4.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 60
4.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 60
4.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 60
4.12 Opportunity and Unmet Need 61
5 Arthritis Therapeutics Market to 2018 - Geographical Landscape 62
5.1 Revenue Analysis by Geography 62
5.2 The US 63
5.2.1 Revenue 63
5.2.2 Annual Cost of Treatment 65
5.2.3 Treatment Usage Patterns 66
5.3 Top Five European countries (UK, Germany, France, Italy and Spain) 68
5.3.1 Revenue 68
5.3.2 Annual Cost of Treatment 69
5.3.3 Treatment Usage Patterns 70
5.4 Japan 72
5.4.1 Revenue 72
5.4.2 Annual Cost of Treatment 73
5.4.3 Treatment Usage Patterns 74
6 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 76
6.1 Introduction 78
6.1.1 Research and Development Pipeline – Osteoarthritis 78
6.2 Introduction 83
6.2.1 Research and Development Pipeline – Rheumatoid Arthritis 83
6.3 Introduction 95
6.3.1 Research and Development Pipeline – Psoriasis Arthritis 95
6.4 Introduction 96
6.4.1 Research and Development Pipeline – Ankylosing Spondylitis 96
6.5 Profiles of Promising Drugs in the Pipeline 98
6.5.1 Tofacitinib (CP-690550) 98
6.5.2 Ofatumumab 99
6.5.3 Secukinumab (AIN457) 99
6.5.4 Fostamatinib (R788) 100
6.5.5 LY2127399 (Tabalumab) 101
6.5.6 REGN88 (SAR153191) 102
6.5.7 LT-NS001 103
7 Arthritis Therapeutics Market to 2018 - Competitive Landscape 104
7.1 Market Share Analysis 104
7.1.1 Major Players 104
7.2 Competitive Profile 105
7.2.1 Roche 105
7.2.2 Johnson & Johnson 107
7.2.3 Pfizer 108
7.2.4 Abbott Laboratories 110
7.2.5 Bristol-Myers Squibb 111
7.2.6 Amgen 112
8 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 113
8.1 Mergers and Acquisitions 113
8.1.1 Overview 113
8.1.2 Major Merger and Acquisition Deals 113
8.1.3 Possible Future Merger and Acquisition Deals 119
8.2 Licensing Agreements 120
8.2.1 Overview 120
8.2.2 Major Licensing Deal 120
8.3 Co-Development Agreements 126
8.4 Deals by Geography 132
8.5 Deals by Value 133
9 Arthritis Therapeutics Market to 2018 - Appendix 134
9.1 Market Definitions 134
9.2 Abbreviations 134
9.3 Sources 135
9.4 Research Methodology 136
9.4.1 Coverage 136
9.4.2 Secondary Research 136
9.4.3 Primary Research 137
9.4.4 Forecasts 137
9.4.5 Expert Panel Validation 140
9.5 Contact Us 140
9.6 Disclaimer 140

1.1 List of Tables
Table 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 15
Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16
Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 16
Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 17
Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 17
Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 18
Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 25
Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 26
Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 26
Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 26
Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 27
Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 28
Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010 29
Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 37
Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 37
Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 38
Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 38
Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 39
Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 40
Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010 41
Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 47
Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 47
Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 47
Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 48
Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 49
Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 49
Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010 50
Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56
Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56
Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57
Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57
Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58
Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59
Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60
Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63
Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63
Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64
Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64
Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65
Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65
Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66
Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66
Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68
Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68
Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69
Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69
Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70
Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71
Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72
Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72
Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73
Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73
Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74
Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74
Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79
Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80
Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80
Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81
Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82
Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82
Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 84
Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 85
Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 86
Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 87
Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 88
Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 89
Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 90
Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 92
Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 93
Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 94
Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 95
Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 96
Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011 97

1.2 List of Figures
Figure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 15
Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 16
Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 17
Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 25
Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 26
Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 27
Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 37
Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 38
Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 39
Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 46
Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 47
Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 48
Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 56
Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 57
Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 58
Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018 62
Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 64
Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 65
Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018 66
Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018 68
Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018 69
Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018 70
Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018 72
Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 73
Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018 74
Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76
Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77
Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78
Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83
Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95
Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96
Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104
Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106
Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107
Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109
Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110
Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111
Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112
Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132
Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133
Figure 41: GBI Research Market Forecasting Model 139